DeepMed Research

Kava

Generic Name: Kava

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₆O_₃

CAS Number: 9000-38-8

Unique Ingredient Identifier: BOW48C81XP

Clinical Trials

Effect of Kava on Anxiety and Stress in Cancer Survivors

Early Phase 1

Recruiting

Conditions: Anxiety
Stress
Sleep
Kava
Cancer
Depression

Interventions: Dietary Supplement: Placebo
Drug: Kava

First Posted Date: 2024-01-19

Last Posted Date: 2025-03-18

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 43

Registration Number: NCT06213298

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence

Phase 2

Recruiting

Conditions: Smoking

Interventions: Drug: AB-free kava
Drug: Placebo

First Posted Date: 2023-04-14

Last Posted Date: 2025-02-05

Lead Sponsor: University of Florida

Target Recruit Count: 76

Registration Number: NCT05814055

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava

Phase 2

Suspended

Conditions: Smoking

Interventions: Drug: Kava
Drug: Placebo

First Posted Date: 2021-10-18

Last Posted Date: 2025-04-25

Lead Sponsor: University of Florida

Target Recruit Count: 80

Registration Number: NCT05081882

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Biomarker Changes and Anxiolytic Effects-Phase 2

Phase 2

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Kava Dietary Supplement
Drug: Placebo

First Posted Date: 2020-09-25

Last Posted Date: 2024-08-13

Lead Sponsor: University of Florida

Target Recruit Count: 39

Registration Number: NCT04565145

Locations: 🇺🇸
UF CTSI Clinical Research Center, Gainesville, Florida, United States

A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Kava Dietary Supplement

First Posted Date: 2019-02-18

Last Posted Date: 2024-06-12

Lead Sponsor: University of Florida

Target Recruit Count: 10

Registration Number: NCT03843502

Locations: 🇺🇸
UF CTSI Clinical Research Center, Gainesville, Florida, United States

Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK

Phase 1

Withdrawn

Conditions: Kava on the Metabolism of Nicotine and NNK

Interventions: Drug: Kava

First Posted Date: 2018-07-31

Last Posted Date: 2020-01-13

Lead Sponsor: University of Florida

Registration Number: NCT03606655

Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)

Phase 2

Terminated

Conditions: Anxiety Disorders

Interventions: Drug: Sugar pill
Drug: Venlafaxine ER
Drug: Kava

First Posted Date: 2004-06-07

Last Posted Date: 2012-10-19

Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Target Recruit Count: 16

Registration Number: NCT00083980

Effects of Kava on the Body's Elimination of Caffeine and Dextromethorphan

Phase 4

Completed

Conditions: Healthy

First Posted Date: 2002-12-10

Last Posted Date: 2008-03-04

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 20

Registration Number: NCT00009542

Locations: 🇺🇸
Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy